Tottenham take legal action against INEOS over withdrawal from sponsorship deal
INEOS, the petrochemical company which owns a minority stake in Manchester United, is being sued by Tottenham Hotspur after withdrawing from a sponsorship agreement with the Premier League club.
In December 2022, Tottenham announced a 'multi-year deal' to make the INEOS Grenadier the team's 'official 4×4 vehicle partner', with the Grenadier logo featuring on headrests in the stadium dugouts and on matchday advertising.
Advertisement
Spurs and INEOS first partnered in 2020 during the Covid-19 pandemic, where it became the club's 'official hand sanitiser supplier'.
On Thursday, Tottenham filed a legal claim against the company's subsidiary INEOS Automotive Limited.
In a statement on Friday, INEOS said: 'We have a contractual right to terminate our partnership contract (with Tottenham) and in December 2024 exercised that right.'
Founded by British billionaire Sir Jim Ratcliffe, INEOS bought a 27.7 per cent stake in United in February 2024, which increased to 28.94 in December 2024 due to a pre-existing commitment at the time of the takeover.
Since becoming part-owner of the club, Ratcliffe has overseen drastic cost-cutting measures at United, which included making 250 staff members redundant last summer and a further 100 in March.
In February, New Zealand Rugby (NZR) launched legal action against INEOS after it allegedly cut short a long-term sponsorship agreement.
NZR claimed that INEOS — which announced what it called a 'unique new six-year partnership' with the rugby body in 2021, beginning in 2022 through to 2028 — did not pay the first instalment of its sponsorship fee for 2025.
In response, INEOS pointed to a change in 'trading conditions' caused by high energy costs and added it had hoped to find a 'managed solution' to the issue.
The two sides confirmed that they had reached an agreement to settle the dispute in April.
INEOS also owns one-third of the successful Mercedes F1 team and the INEOS Grenadiers Tour de France-winning cycling team.
It also owns the INEOS Britannia sailing team, which reached the final of the America's Cup before losing to Emirates Team New Zealand in October, but withdrew its challenge for the next America's Cup in April. It had been announced in January that INEOS had split with team principal and skipper Ben Ainslie, the four-time Olympic champion.
INEOS is also a performance partner of the NN Running Team, comprising over 50 athletes from eight countries.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
Airbus Stock Climbs, Embraer Rallies After Paris Air Show Wins
Dealmaking continued at the 55th Paris Air Show as the showcase of global aerospace technology and economics event headed into day three. Airbus already landed multiple contracts. Brazilian manufacturer Embraer secured a $3.6 billion deal on Wednesday.
Yahoo
38 minutes ago
- Yahoo
McAtee nets opener as England beat Spain to reach U21 Euros semi-finals
James McAtee scored the first goal of the game as England beat Spain 3-1 in the quarter-finals of the 2025 U21 European Championships in Slovakia. Captaining Lee Carsley's side, McAtee pounced on a loose ball to turn home from a few yards out after just 10 minutes. Advertisement That was backed up shortly after by Harvey Elliott, who made the most of a tap in after a low shot was spilled by goalkeeper Alejandro Iturbe. Spain were given a lifeline as half-time approached when Jarrell Quansah tripped Alberto Moleiro in the box. Valencia's Javi Guerra made no mistake from the spot, halving England's lead at the break. With England working hard to keep Spain at arm's length in the second period, McAtee - a creative midfielder who shines on the ball - ran himself into the ground. Our Academy graduate was replaced in the 71st minute as Carsley sought to reinforce further back. Advertisement England held firm and were even able to make the game safe in stoppage time, when Jonathan Rowe was felled by Iturbe in the box. Nottingham Forest's Elliot Anderson converted for the defending champions to ensure safe progress. Speaking after the game, McAtee was only focused on what's to come. "We're over the moon but the focus is the semi-final now," he said. "We got through the group but we knew it wasn't good enough so we had to step it up today so we're glad we got the win." McAtee and England will now face Netherlands at the Slovakian national stadium in Bratislava at 17:00 (UK) on Wednesday 25 June for a place in the final. We'll have a report from that game on and our official app shortly after it concludes.
Yahoo
41 minutes ago
- Yahoo
Piper Sandler Reaffirms Overweight Rating on Soleno (SLNO) Driven by Strong VYKAT XR Prospects
Soleno Therapeutics Inc. (NASDAQ:SLNO) is one of the 10 biotech stocks screaming a buy now. On June 17, Piper Sandler reiterated an 'Overweight' rating on the stock with a $145 price target. The bullish stance follows positive discussions with a European specialist on the company's VYKAT XR medication for Prader-Willi syndrome (PWS). A scientist in a laboratory examining a microscope in the pursuit of cell therapy discoveries. Piper Sandler consulted a UK-based pediatric endocrinologist to understand the drug better. The specialist indicated she would prescribe the drug as medication for Prader-Willi syndrome (PWS) to all eligible patients upon approval. Soleno Therapeutics' edge with the drug stems from the fact that other PWS treatments are in the early stages of development. Piper Sandler believes VYKAT XT represents significant potential as the first approved treatment specifically addressing PWS, a condition. The biotech company plans to file a Marketing Authorization Application for VYKAT XR in the second quarter. It's also pursuing regulatory approval in Europe as it plans to fill with the European Medicines agency. Following regulatory approvals, Soleno Therapeutics Palms will launch the drug in the first quarter of 2026. Soleno Therapeutics is a biopharmaceutical company that develops and commercializes novel treatments for rare diseases. Their lead product, diazoxide choline extended-release tablets (DCCR), is being developed for Prader-Willi syndrome (PWS), specifically to address hyperphagia (excessive hunger). While we acknowledge the potential of SLNO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
